Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

    Diabetes, Obesity and Metabolism Date published:

  • Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD

    Clinical Journal of the American Society of Nephrology Date published:

  • The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

    International Journal of Cardiology Date published:

  • Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2

    Clinical Journal of the American Society of Nephrology Date published:

  • Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

    The Lancet Diabetes & Endocrinology Date published:

  • Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

    Diabetes, Obesity and Metabolism Date published:

  • SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

    Diabetes Date published:

  • Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

    Diabetes, Obesity and Metabolism Date published:

  • Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials

    Journal of the American Society of Nephrology Date published:

  • Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6

    Journal of the American Society of Nephrology Date published:

  • The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial

    Journal of the American Society of Nephrology Date published:

  • International consensus definitions of clinical trial outcomes for kidney failure: 2020

    Kidney International Date published:

  • Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial

    Journal of the American Society of Nephrology Date published:

  • Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories

    Clinical Journal of the American Society of Nephrology Date published:

  • Haemodialysis duration, frequency and intensity for end-stage kidney disease

    Cochrane Database of Systematic Reviews Date published:

  • Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

    Kidney International Date published: